PE20242107A1 - Conjugados que comprenden fosforo (v) y una fraccion molecular de droga - Google Patents

Conjugados que comprenden fosforo (v) y una fraccion molecular de droga

Info

Publication number
PE20242107A1
PE20242107A1 PE2024001005A PE2024001005A PE20242107A1 PE 20242107 A1 PE20242107 A1 PE 20242107A1 PE 2024001005 A PE2024001005 A PE 2024001005A PE 2024001005 A PE2024001005 A PE 2024001005A PE 20242107 A1 PE20242107 A1 PE 20242107A1
Authority
PE
Peru
Prior art keywords
dotted line
bond
double bond
conjugates
phosphorus
Prior art date
Application number
PE2024001005A
Other languages
English (en)
Spanish (es)
Inventor
Christian Hackenberger
Philipp Ochtrop
Jahaziel Jahzerah
Paul Machui
Dominik Schumacher
Jonas Helma-Smets
Isabelle Mai
Marc-Andre Kasper
Original Assignee
Tubulis Gmbh
Forschungsverbund Berlin Ev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tubulis Gmbh, Forschungsverbund Berlin Ev filed Critical Tubulis Gmbh
Publication of PE20242107A1 publication Critical patent/PE20242107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2024001005A 2021-11-09 2022-11-09 Conjugados que comprenden fosforo (v) y una fraccion molecular de droga PE20242107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207195 2021-11-09
PCT/EP2022/081345 WO2023083900A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Publications (1)

Publication Number Publication Date
PE20242107A1 true PE20242107A1 (es) 2024-10-28

Family

ID=78592631

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001005A PE20242107A1 (es) 2021-11-09 2022-11-09 Conjugados que comprenden fosforo (v) y una fraccion molecular de droga

Country Status (15)

Country Link
US (2) US20230330258A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429708A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540691A (cg-RX-API-DMAC7.html)
KR (1) KR20240100413A (cg-RX-API-DMAC7.html)
CN (1) CN118302197A (cg-RX-API-DMAC7.html)
AU (1) AU2022385379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237371A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001372A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005877A2 (cg-RX-API-DMAC7.html)
DE (1) DE22817174T1 (cg-RX-API-DMAC7.html)
ES (1) ES2999335T1 (cg-RX-API-DMAC7.html)
IL (1) IL312675A (cg-RX-API-DMAC7.html)
MX (1) MX2024005546A (cg-RX-API-DMAC7.html)
PE (1) PE20242107A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023083900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321506A (en) * 2022-12-22 2025-08-01 Tubulis Gmbh Conjugates comprising a phosphorus(v) moiety and a drug
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
KR20260065883A (ko) 2023-09-01 2026-05-11 투불리스 게엠베하 포스포나미데이트 화합물의 제조 방법
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
WO2026107136A1 (en) 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates for the treatment of cancer
WO2026105061A1 (en) 2024-11-15 2026-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates that bind cdcp1 and uses thereof
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
WO2018041985A1 (en) 2016-09-01 2018-03-08 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
US12453779B2 (en) 2018-03-07 2025-10-28 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物

Also Published As

Publication number Publication date
AU2022385379A1 (en) 2024-06-20
US20250281634A1 (en) 2025-09-11
CO2024005877A2 (es) 2024-07-08
DE22817174T1 (de) 2024-12-12
KR20240100413A (ko) 2024-07-01
CA3237371A1 (en) 2023-05-19
CN118302197A (zh) 2024-07-05
ES2999335T1 (en) 2025-02-25
CL2024001372A1 (es) 2024-10-25
JP2024540691A (ja) 2024-10-31
EP4429708A1 (en) 2024-09-18
MX2024005546A (es) 2024-07-10
IL312675A (en) 2024-07-01
US20230330258A1 (en) 2023-10-19
WO2023083900A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
PE20242114A1 (es) Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina
CO2024005877A2 (es) Conjugados que comprenden fósforo (v) y una fracción molecular de droga
PE20241299A1 (es) Derivados de exatecan y sus conjugados anticuerpo-farmaco
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
ES2533992T3 (es) Procedimiento para preparar conjugados de anticuerpo maitansinoide
IL263973A (en) Protein-polymer-drug couplings
PE20230467A1 (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
ES2257756T3 (es) Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
AR067182A1 (es) Moduladores del receptor 7 tipo toll
AR117657A1 (es) Conjugados de fármaco que comprenden anticuerpos y derivados de ecteinascidina
NZ588851A (en) Potent conjugates and hydrophilic linkers
JP2024540691A5 (cg-RX-API-DMAC7.html)
MX2025007838A (es) Enlazadores, enlazadores de farmacos y conjugados de los mismos y metodos de uso de los mismos
RU2018120696A (ru) Конъюгаты анти-cd22 антитело-майтансин и способы их применения
MX2026001691A (es) Conjugados que comprenden enlazadores escindibles
PE20251067A1 (es) Conjugado anticuerpo-farmaco msln
ECSP22088584A (es) Conjugados de anticuerpos de fármacos
WO2023006782A1 (en) Conjugating reagents and conjugates thereof
ES2683168T3 (es) Secuencia de escisión específica de MMP-14
JP5649647B2 (ja) 酸に不安定なトリガーユニット
CN111328333B (zh) 一种酸法制备抗体药物偶联物中间体的方法及其应用
KR20250004904A (ko) 친수성 당 구조를 포함하는 리간드-약물 접합체
AR134574A1 (es) Compuesto enlazador modular para conjugados de fármacos de unión a dianas
CA3203849A1 (en) Dual-cleavage ester linkers for antibody-drug conjugates
PE20252273A1 (es) Enlazadores novedosos para el suministro sostenido de terapeuticos